Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NASDAQ:BPMC NASDAQ:DCPH NASDAQ:LEGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$47.37+0.2%$42.30$21.72▼$48.68$8.98B1.232.19 million shs2.22 million shsBPMCBlueprint Medicines$129.46$125.78$73.04▼$129.65$8.36B0.891.55 million shsN/ADCPHDeciphera Pharmaceuticals$25.59$25.59$9.90▼$25.61$2.21B0.191.29 million shs600 shsLEGNLegend Biotech$38.80-0.7%$36.34$27.34▼$59.62$7.18B0.261.37 million shs1.09 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma+0.21%+2.31%+10.60%+22.82%+82.54%BPMCBlueprint Medicines0.00%0.00%+0.98%+23.72%+19.54%DCPHDeciphera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%LEGNLegend Biotech-0.69%-10.52%+8.05%+16.97%-31.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBIOBridgeBio Pharma4.706 of 5 stars4.53.00.03.93.03.30.6BPMCBlueprint Medicines1.0958 of 5 stars2.12.00.00.02.20.80.6DCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ALEGNLegend Biotech3.5818 of 5 stars4.54.00.00.02.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$61.1829.15% UpsideBPMCBlueprint Medicines 2.11Hold$130.000.42% UpsideDCPHDeciphera Pharmaceuticals 0.00N/AN/AN/ALEGNLegend Biotech 2.91Moderate Buy$73.3389.00% UpsideCurrent Analyst Ratings BreakdownLatest DCPH, BBIO, BPMC, and LEGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025BBIOBridgeBio PharmaRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$56.007/29/2025BBIOBridgeBio PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$95.007/21/2025BBIOBridgeBio PharmaTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$66.007/17/2025LEGNLegend BiotechJohnson RiceSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/17/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.007/14/2025BBIOBridgeBio PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $68.007/14/2025BBIOBridgeBio PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.007/11/2025BBIOBridgeBio PharmaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$58.00 ➝ $67.007/10/2025LEGNLegend BiotechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$80.00 ➝ $81.007/9/2025BBIOBridgeBio PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$60.007/8/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$221.90M40.53N/AN/A($7.71) per share-6.14BPMCBlueprint Medicines$562.12M14.87N/AN/A$4.70 per share27.54DCPHDeciphera Pharmaceuticals$174.91M12.65N/AN/A$4.38 per share5.84LEGNLegend Biotech$627.24M11.37N/AN/A$5.70 per share6.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-524.25%N/A-94.43%8/5/2025 (Estimated)BPMCBlueprint Medicines-$67.09M-$2.47N/A199.17N/A-27.70%-64.60%-17.22%8/7/2025 (Estimated)DCPHDeciphera Pharmaceuticals-$194.94M-$2.21N/AN/AN/A-108.86%-52.42%-40.05%N/ALEGNLegend Biotech-$177.03M-$0.59N/AN/AN/A-29.95%-21.19%-13.47%8/11/2025 (Estimated)Latest DCPH, BBIO, BPMC, and LEGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025LEGNLegend Biotech-$0.18N/AN/AN/A$237.49 millionN/A8/7/2025Q2 2025BPMCBlueprint Medicines-$0.54N/AN/AN/A$171.34 millionN/A8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.50N/AN/AN/A$98.46 millionN/A5/13/2025Q1 2025LEGNLegend Biotech-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/ABPMCBlueprint MedicinesN/AN/AN/AN/AN/ADCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A4.574.54BPMCBlueprint Medicines1.012.802.75DCPHDeciphera PharmaceuticalsN/A4.193.94LEGNLegend Biotech0.305.205.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%BPMCBlueprint MedicinesN/ADCPHDeciphera Pharmaceuticals70.96%LEGNLegend Biotech70.89%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%BPMCBlueprint Medicines4.21%DCPHDeciphera Pharmaceuticals4.67%LEGNLegend Biotech0.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400189.88 million155.32 millionOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableDCPHDeciphera Pharmaceuticals30086.48 million82.44 millionOptionableLEGNLegend Biotech2,609183.76 million183.73 millionOptionableDCPH, BBIO, BPMC, and LEGN HeadlinesRecent News About These CompaniesBrokerages Set Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Target Price at $73.331 hour ago | americanbankingnews.comFederated Hermes Inc. Sells 98,629 Shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN)August 1 at 5:23 AM | marketbeat.comDecheng Capital LLC Decreases Stock Holdings in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN)July 30 at 5:38 AM | marketbeat.comLegend Biotech to Host Investor Conference Call on Second Quarter 2025 ResultsJuly 28, 2025 | finance.yahoo.comLegend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 28, 2025 | marketbeat.comLegend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) is IvyRock Asset Management HK Ltd's 3rd Largest PositionJuly 26, 2025 | marketbeat.com177,369 Shares in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Purchased by Readystate Asset Management LPJuly 23, 2025 | marketbeat.comLos Angeles Capital Management LLC Reduces Stock Position in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN)July 22, 2025 | marketbeat.comHC Wainwright Forecasts Legend Biotech Q2 EarningsJuly 21, 2025 | marketbeat.comQ1 EPS Estimates for Legend Biotech Raised by HC WainwrightJuly 18, 2025 | marketbeat.comLegend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?July 18, 2025 | zacks.comHC Wainwright Reaffirms Buy Rating for Legend Biotech (NASDAQ:LEGN)July 17, 2025 | marketbeat.comMassachusetts Financial Services Co. MA Raises Stock Holdings in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN)July 17, 2025 | marketbeat.comCenterBook Partners LP Sells 48,912 Shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN)July 16, 2025 | marketbeat.comLegend Biotech (NASDAQ:LEGN) Given "Buy" Rating at HC WainwrightJuly 8, 2025 | marketbeat.comH.C. Wainwright Maintains a Buy on Legend Biotech (LEGN) With a $75 Price TargetJuly 6, 2025 | msn.comLegend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Shares Acquired by KBC Group NVJuly 5, 2025 | marketbeat.comLegend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives Average Rating of "Moderate Buy" from AnalystsJuly 3, 2025 | marketbeat.comA Glimpse Into The Expert Outlook On Legend Biotech Through 6 AnalystsJuly 2, 2025 | benzinga.comLegend Biotech (NASDAQ:LEGN) Given New $54.00 Price Target at UBS GroupJuly 2, 2025 | marketbeat.comKrane Funds Advisors LLC Purchases 22,036 Shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN)July 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDCPH, BBIO, BPMC, and LEGN Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$47.37 +0.10 (+0.21%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$47.00 -0.37 (-0.78%) As of 08/1/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Blueprint Medicines NASDAQ:BPMC$129.46 0.00 (0.00%) As of 07/18/2025Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Deciphera Pharmaceuticals NASDAQ:DCPHDeciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.Legend Biotech NASDAQ:LEGN$38.80 -0.27 (-0.69%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$38.81 +0.01 (+0.03%) As of 08/1/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
